Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD4 Antigens · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CD4 Antigens | DRUG | - |
Inclusion Criteria Patients must have: * HIV-1 seropositivity. * Diagnosis of AIDS or AIDS related complex (ARC). * Failure to tolerate or respond to zidovudine (AZT) or decided to decline AZT therapy. * The ability to sign a written informed consent form prior to treatment. * A willingness to abs...
Top 20 of 28 competitors
CD4 Antigens is an investigational small molecule being studied for the treatment of HIV Infections. It is currently in Phase 1 clinical development, meaning it has not yet been approved and is still being evaluated for safety and efficacy in clinical trials.
CD4 Antigens is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational therapy for HIV Infections.
CD4 Antigens is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and pharmacokinetics.
CD4 Antigens has one completed Phase 1 clinical trial, identified as NCT00002004. This study evaluated the safety and pharmacokinetics of recombinant CD4 (rCD4) in patients with AIDS and AIDS-Related Complex in the United States.
CD4 Antigens is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for HIV Infections. The drug has completed one early-stage trial, but it has not yet received regulatory approval for any use.